Neuren Pharmaceuticals (OTCMKTS:NURPF) Stock Price Down 13.5% – Should You Sell?

Shares of Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) were down 13.5% during mid-day trading on Monday . The company traded as low as C$8.53 and last traded at C$8.53. Approximately 2,010 shares were traded during trading, an increase of 104% from the average daily volume of 987 shares. The stock had previously closed at C$9.86.

Neuren Pharmaceuticals Price Performance

The company has a 50-day moving average price of C$11.96 and a 200-day moving average price of C$12.34.

Neuren Pharmaceuticals Company Profile

Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.

The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome.